These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21543341)

  • 1. Back to the future: mechanism-based, mutation-specific combination chemoprevention with a synthetic lethality approach.
    Meyskens FL; Gerner EW
    Cancer Prev Res (Phila); 2011 May; 4(5):628-32. PubMed ID: 21543341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lung-cancer chemoprevention by induction of synthetic lethality in mutant KRAS premalignant cells in vitro and in vivo.
    Huang S; Ren X; Wang L; Zhang L; Wu X
    Cancer Prev Res (Phila); 2011 May; 4(5):666-73. PubMed ID: 21543344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An intermittent approach for cancer chemoprevention.
    Wu X; Lippman SM
    Nat Rev Cancer; 2011 Nov; 11(12):879-85. PubMed ID: 22071977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applying synthetic lethality for the selective targeting of cancer.
    McLornan DP; List A; Mufti GJ
    N Engl J Med; 2014 Oct; 371(18):1725-35. PubMed ID: 25354106
    [No Abstract]   [Full Text] [Related]  

  • 5. Novel multiple, monoallelic KRAS mutations at codon 12 and 13.
    Keller G; Geist B; Slotta-Huspenina J; Langer R; Nagl F; Fend F; Höfler H; Perren A
    Int J Cancer; 2009 Dec; 125(11):2744-5. PubMed ID: 19521964
    [No Abstract]   [Full Text] [Related]  

  • 6. [Basic principles for the prevention, diagnosis and therapy of lung cancer].
    Gyula O; András B; Zoltán B; Katalin B; Attila C; Janos F; Maria G; Akos H; Lászlo K; Lászlo K; Gabor K; Gyorgy L; Judit M; Tamas MF; Zsuzsa M; Pál R; Zsolt O; János S; Zoltán S; István S; Klára S; Jozsef T; Edina T;
    Magy Onkol; 2012 May; 56(2):114-32. PubMed ID: 22724157
    [No Abstract]   [Full Text] [Related]  

  • 7. Isolation of a chemical inhibitor against K-Ras-induced p53 suppression through natural compound screening.
    Lee SJ; Jung YS; Lee SH; Chung HY; Park BJ
    Int J Oncol; 2009 Jun; 34(6):1637-43. PubMed ID: 19424582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.
    Dragnev KH; Ma T; Cyrus J; Galimberti F; Memoli V; Busch AM; Tsongalis GJ; Seltzer M; Johnstone D; Erkmen CP; Nugent W; Rigas JR; Liu X; Freemantle SJ; Kurie JM; Waxman S; Dmitrovsky E
    Cancer Prev Res (Phila); 2011 Jun; 4(6):818-28. PubMed ID: 21636548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitochondrial DNA mutations in respiratory complex-I in never-smoker lung cancer patients contribute to lung cancer progression and associated with EGFR gene mutation.
    Dasgupta S; Soudry E; Mukhopadhyay N; Shao C; Yee J; Lam S; Lam W; Zhang W; Gazdar AF; Fisher PB; Sidransky D
    J Cell Physiol; 2012 Jun; 227(6):2451-60. PubMed ID: 21830212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS mutation analysis helps to differentiate between pulmonary metastasis from colon adenocarcinoma in situ and primary lung adenocarcinoma.
    Ortiz TM; Cohen DW; Kent MS; Jänne PA; Costa DB
    J Thorac Oncol; 2011 Jan; 6(1):220-2. PubMed ID: 21178719
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of Kras gene mutation and copy number in thymic carcinomas and thymomas.
    Sasaki H; Yano M; Fujii Y
    J Thorac Oncol; 2010 Oct; 5(10):1715-6. PubMed ID: 20871271
    [No Abstract]   [Full Text] [Related]  

  • 12. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
    Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
    BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations.
    Park IH; Kim JY; Jung JI; Han JY
    Invest New Drugs; 2010 Dec; 28(6):791-9. PubMed ID: 19760159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001.
    Mohseni M; Park BH
    J Clin Invest; 2010 Aug; 120(8):2655-8. PubMed ID: 20664174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
    Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic lethal genetic screens in Ras mutant cancers.
    Yu B; Luo J
    Enzymes; 2013; 34 Pt. B():201-19. PubMed ID: 25034106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic lethality-based therapeutics: perspectives for applications in colorectal cancer.
    Soncini D; Caffa I; Patrone F; Ballestrero A; Nencioni A
    Curr Cancer Drug Targets; 2012 May; 12(4):329-38. PubMed ID: 22385509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.
    Fischer M; Yen WC; Kapoun AM; Wang M; O'Young G; Lewicki J; Gurney A; Hoey T
    Cancer Res; 2011 Mar; 71(5):1520-5. PubMed ID: 21193546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted treatment for lung cancer could be possible due to identification of nonuniform genetic mutations.
    Jones S
    Pharmacogenomics; 2014 May; 15(7):903-4. PubMed ID: 25090664
    [No Abstract]   [Full Text] [Related]  

  • 20. Scrib heterozygosity predisposes to lung cancer and cooperates with KRas hyperactivation to accelerate lung cancer progression in vivo.
    Elsum IA; Yates LL; Pearson HB; Phesse TJ; Long F; O'Donoghue R; Ernst M; Cullinane C; Humbert PO
    Oncogene; 2014 Nov; 33(48):5523-33. PubMed ID: 24276238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.